Jan Lötvall,
Professor,
University of Gothenburg; Founding President of ISEV; Editor-in-Chief, Journal of Extracellular Vesicles
Jan Lötvall is Professor at the Institute of Medicine at Göteborg University since 2002 where he directs a research laboratory studying extracellular vesicles. He is a medical specialist in both Clinical Allergy and Clinical Pharmacology, and has a long-term experience in translational studies in primarily inflammation, but also cancer. He was first elected President of the International Society for Extracellular Vesicles (ISEV, 2011-2016), a rapidly growing non-profit organisation in the field of exosomes, microvesicles and other extracellular vesicles (www.isev.org; >1100 members). The research line focusing on extracellular vesicle biology has received extensive international recognition, as the lab was first to discover the ability of exosomes to shuttle RNA between cells in 2007. During the period of May 2016 to January 2018, JL served as Chief Scientist at Codiak BioSciences, a startup biotech company focusing on developing exosomes as a therapeutic platform. From January 2018, JL was the founding editor of the journals “Clinical and Translational Allergy” (2011, IF 3.239) and Journal of Extracellular Vesicles (JEV: IF 14.9). JL is the current Editor-in-Chief of JEV since August 2019. He is also the Chief Executive Officer and Chief Scientific Officer of Exocure Biosciences, a privately held vesicle therapeutics company.
Engineered Synthetic Bacterial Vesicles as Cancer Immunotherapy and as Vaccines against Bacteria and SARS-CoV-2
Tuesday, 1 March 2022 at 18:00
Add to Calendar ▼2022-03-01 18:00:002022-03-01 19:00:00Europe/LondonEngineered Synthetic Bacterial Vesicles as Cancer Immunotherapy and as Vaccines against Bacteria and SARS-CoV-2Circulating Biomarkers, Exosomes and Liquid Biopsy Europe 2022 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
We are developing a novel platform of “exosome-like” synthetic bacterial vesicles (SyBV) that can be utilized as cancer immunotherapy, and as preventive vaccines against viral or bacterial infection. Briefly, the SyBV are produced from isolated bacterial membranes, and exhibit many of the features of natural bacterial veicles (OMV), but have been detoxified efficiently by removal of multiple bacterial components that activate pattern recognition receptors (PRR), including Toll Like Receptors (TLR). This strongly reduces the dose-limiting side effects of the SyBVs, but retains their stimulatory effects on adaptive immunity. The SyBV efficiently induce specific immunity via T-cell and humoral responses in both cancer models, and against bacterial components. SyBV combined with tumor exosomes induce immune responses in models of malignant melanoma and colon cancer, and synergize with checkpoint inhibitors to reduce or stop tumor growth. Further, SyBV can function as adjuvant in virus vaccine candidates, including SARS-CoV-2. SyBV is a safe and highly efficient platform with potentially very wide clinical applications in both cancer immunotherapy, as well as preventive vaccines against both bacterial and viral infections.
Add to Calendar ▼2022-03-01 00:00:002022-03-02 00:00:00Europe/LondonCirculating Biomarkers, Exosomes and Liquid Biopsy Europe 2022Circulating Biomarkers, Exosomes and Liquid Biopsy Europe 2022 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com